Pharmacokinetic Clinical Trial
Official title:
Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults
1. To explore the relationship between the changes of plasma concentration of abiraterone acetate after taken orally on fasting or postprandial and gene polymorphism. 2. Study of drug Metabolite profiling after oral administration of abiraterone acetate on fasting and postprandial in Chinese adults.
Prostate cancer is the most common malignancy in men currently, second only to lung cancer in China. And in Europe and America, it has already overtaken lung and bowel cancer and become the greatest threat of of men's health. After the diagnosis of high-risk prostate cancer patients, endocrine therapy is still the main treatment. It is effective for most patients who receive androgen deprivation therapy at first. However, after the remission whose median time is 18 to 24 months through endocrine therapy, most patients will turn to castration resistant prostate cancer (CRPC). The treatment of CRPC has always been a difficult point , and now it has become the emphasis of new endocrine drug development for prostate cancer. Abiraterone acetate tablets in combination with prednisone apply to the treatment of metastatic castration-resistant prostate cancer. It has been approved by the US Food and Drug Administration in 2011 and gotten listing license in China. Abiraterone acetate is an effective irreversible inhibitor CYP17 enzyme and can be converted into abiraterone in vivo. Abiraterone is an androgen biosynthesis inhibitor with a high affinity and selectivity to CYP17. The inhibitory activity of abiraterone for CYP17 was 10-30 times higher than that of ketoconazole. Androgen biosynthesis is inhibited by inhibiting CYP17. The results of many large-scale clinical trials showed that abiraterone acetate could effectively prolong survival time of the patients . In this study, Blood and plasma samples, urine and faeces samples in 72h from healthy Chinese adult volunteers who have taken abiraterone acetate tablet orally on an empty stomach or after meals were collected for metabolite analysis, the relationship between plasma concentration and gene polymorphism, and identifying the major metabolites in metabolic biological samples to reveal the pharmacokinetic characteristics of abiraterone acetate tablets，demonstrate the pharmacodynamic mechanism，and explore the effect of different genotypes Pharmacokinetic characteristics in healthy Chinese adults. The result provides theoretical basis for clinical rational drug use. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04531150 -
Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects
|
Phase 1 | |
| Completed |
NCT03437265 -
A Pharmacokinetic Study of PLENVU® in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03979989 -
Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)
|
Phase 1 | |
| Completed |
NCT00743912 -
Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT05367011 -
Therapeutic Monitoring of Antibiotics in Intensive Care Patients: a Cohort Study PopTDM-ICU
|
||
| Completed |
NCT06126562 -
A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00745264 -
Multi-Centre, Open-Label, Two Segment, Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise
|
Phase 1 | |
| Completed |
NCT03344627 -
Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients
|
N/A | |
| Completed |
NCT01082796 -
Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects
|
N/A | |
| Terminated |
NCT02696954 -
Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03714568 -
Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.
|
Phase 1 | |
| Recruiting |
NCT04080895 -
Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03011996 -
To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration
|
Phase 1 | |
| Completed |
NCT00681395 -
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
|
Phase 1 | |
| Completed |
NCT04617509 -
A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248
|
Phase 1 | |
| Not yet recruiting |
NCT06344858 -
Characterization of the Temporal Profile of the Anti-nociceptive Effect of Ketamine Bolus Measured With ANI
|
||
| Terminated |
NCT03059511 -
Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants
|
Phase 1 | |
| Not yet recruiting |
NCT05938608 -
A Study to Assess the Availability of Oral Primaquine and Its Inert Metabolite, Carboxyprimaquine, in the Body
|
Phase 1 | |
| Completed |
NCT01091532 -
A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.
|
Phase 1 | |
| Completed |
NCT03951402 -
Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women
|
Phase 1 |